UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 29

Sortiert nach

Molecular Biology and Therapeutic Perspectives for K-Ras Mutant Non-Small Cell Lung Cancers

Cancers, 2022-08, Vol.14 (17), p.4103

2022

Link zum Volltext

Verfügbarkeit prüfen

SAKK 19/17: safety analysis of first-line durvalumab in patients with PD-L1 positive, advanced nonsmall cell lung cancer and a performance status of 2

Cancer Immunology, Immunotherapy, 2021-05, Vol.70 (5), p.1255-1262

2021

Link zum Volltext

Verfügbarkeit prüfen

Correlation of KRAS G12C Mutation and High PD-L1 Expression with Clinical Outcome in NSCLC Patients Treated with Anti-PD1 Immunotherapy

Journal of clinical medicine, 2022-03, Vol.11 (6), p.1627

2022

Link zum Volltext

Verfügbarkeit prüfen

Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: A multicenter phase II trial (SAKK 19/05)

Lung cancer (Amsterdam, Netherlands), 2012-12, Vol.78 (3), p.239-244

2012

Link zum Volltext

Verfügbarkeit prüfen

Impact of 18F-FDG PET/CT in Staging Patients With Small Cell Lung Cancer: A Systematic Review and Meta-Analysis

Frontiers in medicine, 2020-01, Vol.6, p.336-336

2020

Link zum Volltext

Verfügbarkeit prüfen

Overview of recent advances in molecular analysis for diagnosing early stage lung cancer nodules

Translational lung cancer research, 2021-11, Vol.10 (11), p.4303-4307

2021

Link zum Volltext

Verfügbarkeit prüfen

Clinical Outcome of ALK-Positive Non–Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs)

Journal of thoracic oncology, 2017-04, Vol.12 (4), p.681-688

2017

Link zum Volltext

Verfügbarkeit prüfen

Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry

Journal of clinical oncology, 2017-05, Vol.35 (13), p.1403-1410

2017

Link zum Volltext

Verfügbarkeit prüfen

First-line durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2). Primary analysis of the multicenter, single-arm phase II trial SAKK 19/17

European journal of cancer (1990), 2024-03, Vol.200, p.113600-113600, Article 113600

2024

Link zum Volltext

Verfügbarkeit prüfen

First line (1L) durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2): Primary analysis of the multicenter, single-arm phase II trial SAKK 19/17

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.9088-9088

2023

Link zum Volltext

Verfügbarkeit prüfen

Real-world outcomes of patients (pts) with malignant solid tumors treated with immune checkpoint inhibitors (ICI) in relation to smoking status: The SAKK 80/19 SMOKER study

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.6619-6619

2023

Link zum Volltext

Verfügbarkeit prüfen

Pembrolizumab as Palliative Immunotherapy in Malignant Pleural Mesothelioma

Journal of thoracic oncology, 2018-11, Vol.13 (11), p.1784-1791

2018

Link zum Volltext

Verfügbarkeit prüfen

Patients with EGFR mutant (m) MET-altered NSCLC receiving tepotinib with an EGFR tyrosine kinase inhibitor (TKI): A case series

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.9070-9070

2023

Link zum Volltext

Verfügbarkeit prüfen

Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial

The lancet respiratory medicine, 2017-05, Vol.5 (5), p.435-444

2017

Link zum Volltext

Verfügbarkeit prüfen

Binimetinib, pemetrexed and cisplatin, followed by maintenance of binimetinib and pemetrexed in patients with advanced non-small cell lung cancer (NSCLC) and KRAS mutations. The phase 1B SAKK 19/16 trial

Lung cancer (Amsterdam, Netherlands), 2021-06, Vol.156, p.91-99

2021

Link zum Volltext

Verfügbarkeit prüfen

GLASS: Global Lorlatinib for ALK(+) and ROS1(+) retrospective Study: real world data of 123 NSCLC patients

Lung cancer (Amsterdam, Netherlands), 2020-10, Vol.148, p.48-54

2020

Link zum Volltext

Verfügbarkeit prüfen

PUB100 Clinical Outcomes of Non-Small Cell Lung Cancer (NSCLC) Patients with ALK Co-Mutations (EGFR or KRAS) Receiving Tyrosine Kinase Inhibitors (TKI)

Journal of thoracic oncology, 2017-01, Vol.12 (1), p.S1505-S1505

2017

Link zum Volltext

Verfügbarkeit prüfen

SAKK 16/14: Anti-PD-L1 antibody durvalumab in addition to neoadjuvant chemotherapy in patients with stage IIIA(N2) non-small cell lung cancer (NSCLC)—A multicenter single-arm phase II trial

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.9016-9016

2020

Link zum Volltext

Verfügbarkeit prüfen

Impact of the systematic introduction of low-cost bubble nasal CPAP in a NICU of a developing country: a prospective pre- and post-intervention study

BMC pediatrics, 2015-03, Vol.15 (1), p.26-26, Article 26

2015

Link zum Volltext

Verfügbarkeit prüfen

Management of non-small cell lung cancer in the elderly

European journal of internal medicine, 2014-12, Vol.25 (10), p.888-894

2014

Link zum Volltext

Verfügbarkeit prüfen

Impact of 18 F-FDG PET/CT in Staging Patients With Small Cell Lung Cancer: A Systematic Review and Meta-Analysis

Frontiers in medicine, 2019, Vol.6, p.336

2019

Link zum Volltext

Verfügbarkeit prüfen

MA16.03 Global RET Registry (GLORY): Activity of RET-Directed Targeted Therapies in RET-Rearranged Lung Cancers

Journal of thoracic oncology, 2017-01, Vol.12 (1), p.S435-S436

2017

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 29

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(28)
Mit Volltextzugriff
(29)

Publikationsform

Artikel
(29)

Sprache

Englisch
(29)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(19)
Science & Technology
(19)
Humans
(14)
Oncology
(14)
Male
(11)
Aged
(10)
Female
(10)
Aged, 80 And Over
(8)
Middle Aged
(8)
Respiratory System
(8)
Adult
(7)
Lung Neoplasms - Drug Therapy
(7)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(6)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(6)
Treatment Outcome
(6)
Lung Cancer
(5)
Lung Neoplasms - Pathology
(5)
Mutation
(5)
Carcinoma, Non-Small-Cell Lung - Genetics
(4)
Carcinoma, Non-Small-Cell Lung - Mortality
(4)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Molecular Biology and Therapeutic Perspectives for K-Ras Mutant Non-Small Cell Lung Cancers

SAKK 19/17: safety analysis of first-line durvalumab in patients with PD-L1 positive, advanced nonsmall cell lung cancer and a performance status of 2

Correlation of KRAS G12C Mutation and High PD-L1 Expression with Clinical Outcome in NSCLC Patients Treated with Anti-PD1 Immunotherapy

Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: A multicenter phase II trial (SAKK 19/05)

Impact of 18F-FDG PET/CT in Staging Patients With Small Cell Lung Cancer: A Systematic Review and Meta-Analysis

SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non–Small-Cell Lung Cancer—A Multicenter Single-Arm Phase II Trial

Overview of recent advances in molecular analysis for diagnosing early stage lung cancer nodules

Clinical Outcome of ALK-Positive Non–Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs)

Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry

First-line durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2). Primary analysis of the multicenter, single-arm phase II trial SAKK 19/17

First line (1L) durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2): Primary analysis of the multicenter, single-arm phase II trial SAKK 19/17

Real-world outcomes of patients (pts) with malignant solid tumors treated with immune checkpoint inhibitors (ICI) in relation to smoking status: The SAKK 80/19 SMOKER study

Pembrolizumab as Palliative Immunotherapy in Malignant Pleural Mesothelioma

Patients with EGFR mutant (m) MET-altered NSCLC receiving tepotinib with an EGFR tyrosine kinase inhibitor (TKI): A case series

SAKK 16/18: Immune-modulatory radiotherapy to enhance the effects of neoadjuvant PD-L1 blockade after neoadjuvant chemotherapy in patients with resectable stage III (N2) non-small cell lung cancer (NSCLC)—A multicenter phase II trial

Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial

Binimetinib, pemetrexed and cisplatin, followed by maintenance of binimetinib and pemetrexed in patients with advanced non-small cell lung cancer (NSCLC) and KRAS mutations. The phase 1B SAKK 19/16 trial

GLASS: Global Lorlatinib for ALK(+) and ROS1(+) retrospective Study: real world data of 123 NSCLC patients

PUB100 Clinical Outcomes of Non-Small Cell Lung Cancer (NSCLC) Patients with ALK Co-Mutations (EGFR or KRAS) Receiving Tyrosine Kinase Inhibitors (TKI)

SAKK 16/14: Anti-PD-L1 antibody durvalumab in addition to neoadjuvant chemotherapy in patients with stage IIIA(N2) non-small cell lung cancer (NSCLC)—A multicenter single-arm phase II trial

Impact of the systematic introduction of low-cost bubble nasal CPAP in a NICU of a developing country: a prospective pre- and post-intervention study

Management of non-small cell lung cancer in the elderly

Impact of 18 F-FDG PET/CT in Staging Patients With Small Cell Lung Cancer: A Systematic Review and Meta-Analysis

Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Maintenance Therapy for Patients With Advanced Nonsquamous Non–Small-cell Lung Cancer: Update From the Swiss Group for Clinical Cancer Research (SAKK) 19/09 Trial

MA16.03 Global RET Registry (GLORY): Activity of RET-Directed Targeted Therapies in RET-Rearranged Lung Cancers

Suchergebnisse filtern